Book Description HTML
Dominex Pharmaceuticals must get their new drug on the market or the company will go under. Pay offs for quick approvals won’t work this time. The new gatekeeper at the FDA plays by the book. To maneuver around this new obstacle, the company orchestrates a creatively deceptive plan, using 500 study volunteers towards a deadly result.